Oncolytics Biotech INC Form 4 insider transactions

Oncolytics Biotech Inc. reports the grant of stock options to Director Angela Holtham, with vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Director James T. Parsons, with vesting over three years.

Oncolytics Biotech reports the Chief Financial Officer, Kirk Look, was granted 260,000 stock options with an exercise price of $1.06, vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Business Officer Andrew Aromando, with vesting over three years.

Jared Kelly, CEO of Oncolytics Biotech, received stock options for 755,000 shares with an exercise price of $1.06, vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Technology Officer Allison Hagerman, with specific vesting conditions and an exercise price tied to the stock's closing price on the grant date.

Deborah Margaret Brown, a Director at Oncolytics Biotech Inc., was granted 30,000 stock options with an exercise price of $1.06, vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Medical Officer Thomas Charles Heineman.

Oncolytics Biotech Inc. reports the grant of stock options to Chief Operating Officer John Bearden McAdory, with vesting over three years.

Oncolytics Biotech Inc. reports the grant of stock options to Director Stephen C. Glover, with an exercise price tied to the stock's closing price on the grant date.

Oncolytics Biotech Director James T. Parsons acquired 10,000 common shares at $1.03 each, increasing his direct beneficial ownership to 41,849 shares.

Oncolytics Biotech Inc. CEO Jared Kelly acquired 5,050 common shares at $0.96 per share, increasing his direct beneficial ownership.

ONCOLYTICS BIOTECH INC's CEO, Jared Kelly, increased his direct beneficial ownership by purchasing 35,100 common shares over two days in February 2026.

Oncolytics Biotech CFO Kirk Look disclosed a planned future purchase of 12,000 common shares under a Rule 10b5-1 plan.

ONCOLYTICS BIOTECH Director Wayne Pisano acquired 30,000 common shares at a weighted average price of $0.8446.

Oncolytics Biotech's Chief Medical Officer, Thomas Charles Heineman, acquired 12,132 common shares at $0.827 each, increasing his direct beneficial ownership.

Oncolytics Biotech Inc. Director Deborah Margaret Brown acquired 25,000 common shares at a weighted average price of $0.8496.

Oncolytics Biotech Inc.'s VP of Product Development, Allison Hagerman, purchased 10,000 common shares at $0.8298 each, increasing her direct beneficial ownership to 115,059 shares.

ONCOLYTICS BIOTECH Director Bernd R. Seizinger acquired 100,000 common shares through two open market purchases in February 2026.

ONCOLYTICS BIOTECH INC's Chief Business Officer, Andrew Aromando, acquired 29,600 common shares at a weighted average price of $0.8587.

ONCOLYTICS BIOTECH Director Patricia S. Andrews acquired 35,400 common shares, increasing her beneficial ownership.

ONCOLYTICS BIOTECH INC Director Bernd R. Seizinger acquired 100,000 common shares at an average price of $1.0377, increasing his direct beneficial ownership to 466,991 shares.

Oncolytics Biotech Inc. outlines strategic reasons for its proposed change of incorporation jurisdiction from Alberta, Canada, to Nevada, U.S.